Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Other EventsItem 8.01. Other Events
On March 26, 2018, Immune Therapeutics, Inc., a Florida corporation (the “Company”) published a press release (the “Press Release”) announcing that it received minutes from the Type C meeting held on January 16, 2018, between the Company on behalf of Cytocom, Inc., the license holder, and the US Food and Drug Administration to discuss next steps in the development of IRT-103 “Lodonal”™, an oral once-a-day adjunct therapy to the standard of care for moderate to severe Crohn’s disease in adults and mild to severe in pediatric patients. The Press Release is attached hereto as exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
| Exhibit No. | Description |
| 99.1 | Press Release |
Immune Therapeutics, Inc. ExhibitEX-99.1 2 ex99-1.htm Immune Therapeutics,…To view the full exhibit click here
About Immune Therapeutics, Inc. (OTCMKTS:IMUN)
Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer.
